

Scientific Ethical Integrity and Human Research Subjects Protections Non-compliance Remediation: Commentary on Practical Considerations and Implications

Ralph J Johnson^{1,2,*}

¹Research PA-C/Research Coordinator, University of Texas MD Anderson Cancer Center

²Chaplain, Texas Medical Center Catholic Chaplaincy Corp.

Corresponding author:

Ralph Jay Johnson, Ph.D., PA-C, M.A.H.S., M.AT. Dept. of Lymphoma/Myeloma, UT-MDACC, Unit 42, 1515 Holcombe Blvd. Houston, TX, 77030. U.S.A. 832-372-3511

Running Title:

Remediation for Human Research Subjects Protections Non-Compliance: Practical Considerations and Implications

Keywords:

Human research subjects protections; Research regulatory non-compliance; Remediation; Study Reclamation; Scientific Misconduct

Received: Mar 15, 2022

Accepted: Mar 21, 2022

Published: Mar 22, 2022

Editor:

Raul Isea, Fundación Instituto de Estudios Avanzados -IDEA

DOI 10.14302/issn.2576-9383.jhhr-22-4138

Abstract

Medical science's advancements depend on preserving its credibility and the public trust, though as a human institution it is fallible and liable to ethical breaches that can void public confidence and support. There is no more egregious ethical departure than deviations / violations of Human Research Subjects Protections (i.e., non-compliance), which is remarkable given they are fairly widespread and often repeated. Once uncovered, this generally should result in the research's suspension or termination. Yet, there is a third option to preserve valuable and worthy research that went awry due to lapses in Human Research Subjects Protections, specifically, Remediation. Due to the sequestered nature of Remediation, little has been reported on its processes, and practically nothing, regarding practical considerations, recommendations, and implications for the remediation workers themselves—for this line of work is perilously risky. This commentary reports some of those best-practices, "first-hand grittier in-the-trenches" informed practical lessons learned. Implications are discussed in the interest of improving the reasonable, balanced, and competent

ethical conduct of research, addressing / avoiding Human Subjects Protections ethical non-compliance, and avenues for further inquiry regarding Remediation.

Introduction

Medical science is a vital and principal institution due to its promises of a far-reaching and alluring compendium of advancements through which there is greater predictability, control, and improvement in the human condition.[1-3] Nevertheless, it is a human institution—fallible, and prone to ethical breaches, misconduct and breaks from scientific integrity.[3-7] Thus, preservation of the scientific enterprise's credibility and the public trust vested in it is predicated on ensuring sound scientific integrity. In the post-modern era, with rapid dissemination of information and increased democratic processes, the risk of accusations of breaks in scientific integrity is magnified greatly.[9-10] The loss of public confidence in medical scientific research institutions may corrosively erode public support for medical scientists and their research programs everywhere.[3,9,11,12] Concern should be paramount and ubiquitous for preserving scientific integrity and to achieve reclamation, if possible, where there have been ethical breaches in otherwise valuable and meaningful research. [3,13-16]

Probably there is no more egregious ethical breach of scientific integrity in medical research than deviations or violations (i.e., non-compliance) of Human Research Subjects Protections, especially anything abrogating adequate informed consent to participate in research (e.g., no consent obtained, wrong consent, language not translated, improperly completed consent, consent P&P not followed, consent undocumented, etc.).[17-19, 20] The integrity of Human Research Subjects Protections is commonly considered inviolable and sacrosanct.[20] Unfortunately, violations are fairly common, even though there are a plethora of formally established safeguards, policies, procedures, regulations and agencies and agents, as well as punitive sanctions for such violations.[21-25] A

large proportion of scientific research wrongdoing (approximately 50%) falls under the rubric of Human Research Subjects Protections non-compliance, with nearly 100% attributable to “Failure to Follow Procedures.”[19] Conservatively, there are estimates over a two-year period of about 1,200 - 2,150 cases in the U.S. per year alone. No one can be exactly sure, because they are sensitive cases and therefore kept secret.[22, 27] Furthermore, most of the known offenders tend to be repeat offenders, even with multiple layers of prevention for recidivists. [26,28]

Background

Typically, after an audit finds substantial, continued, and patterned deviations, violations, and abuses, an Institutional Review Board (IRB) assigns a level of non-compliance; based on this level, there are two formal absolute options: suspension or termination.[29-32] However, there is a 3rd informal option of Remediation, depending on whether the research is valuable, worthy, and can be redeemed through restitution and reclamation, restoration of trust, significant risk management, remorse and contrition, and establishing preventive plans of actions to avoid recidivism.[22,33-36] Remediation offers scientific research institutions and agencies opportunities for reclaiming and salvaging otherwise worthwhile research studies that went astray due Human Research Subjects Protections non-compliance.[16,22, 35,36]

Human Research Subjects Protections Deviation / Violation remediation projects may be widespread and fairly common—so much so that IRBs employ a common acronym: “HRSPD/V-CAPA” or “CAPA” for short (i.e., Corrective And Preventive Action plan) to describe them.[37,38,cf.39] Yet, little has been written and virtually no formal research has been done on how they are conducted, much less the practical implications for those burdened with conducting them.[22,39,40] Note: there are probably about as many Human Research Subjects Protections-related CAPAs as there are scientific

research-intensive institutions.[41,42] But any formal reports are usually vague summaries void of practical detail and limited to the extent IRBs require public dissemination and demonstrations of open contrition and penitence.[30,31] This is probably the consequence of their embarrassing and sensitive nature, so that only direct participants are truly privy to them.[17-20] Thus, the world of Human Research Subjects Protections non-compliance remediation is one that is a “known secret”—but dark, murky, nebulous and rarely discussed in public venues unless mandated, and then only to the extent mandated.[22]

Purpose

A substantial number of Human Research Subjects Protections CAPAs also are a testament to the notion that valuable scientific research studies can and do make related mistakes, but these can be redeemed through remediation. [3,13-16, 22] Yet, formal empirical studies on Human Research Subjects Protections violation remediation would be an admission that an egregious, non-condoned, profane violation occurred of something considered sanctified. “It is not supposed to happen, but it does, and how it is done and what does that mean for the one(s) who have to do it has been as-of-yet unspoken.”[43,44] Nevertheless, given that these affairs and their repair are apparently widespread, and to fill the gap regarding this vital information, the purpose of this article is to provide some informed conceptual yet practical lessons learned on involvement with Human Research Subjects Protections non-compliance remediation projects—particularly from the perspective and best interests of those directly involved with them. The points derive from the author’s first-hand experience with repairing, reclaiming, and resurrecting multiple errant research studies that were temporarily suspended due to Human Research Subjects Protections deviations and violations at multiple research-intensive institutions. Though the perspective is that of an outsider or distanced party brought-in and specifically tasked with fixing up, cleaning up and restoring a study or studies to ethical

health, the advice, guidance, and recommendations are just as relevant to insiders involved with Human Research Subjects Protections Violation remediation.

Commentary

First, Human Research Subjects Protections Violation remediation projects can be extremely expensive and labor-intensive, as they probably will involve painstakingly re-conducting work that was done wrong or not at all for substantial numbers of human research subjects (e.g., hundreds, if not in the thousands). [45] “Remediation is a third option, but it is no free pass.”[22] Also, remediation projects tend to be painful, ugly, and even dreadful affairs in that they involve an admission of extreme wrongdoing regarding a subject that should be sacrosanct—the defilement of which definitely is in the realm of professional discretization. So finger-pointing, “backbiting,” and recriminations are not unusual—not to mention concerns about that ‘the competitors in a highly competitive field might take the information and run with it should it leak out and become public.’ The best possible course of action to counter all this is quickly: “To get it out, you get it out, and you take control.”[46] Taking control involves transitioning quickly to acceptance of what happened, an accurate and visual needs assessment of the extent of wrongdoing, and the fast development of a course of action to correct it—and then implementing the plan as quickly and with as little fanfare as possible.[22,46] Also, it is better to propose a workable resolution developed from accurate data to the IRB and/or other regulatory agencies rather than have them propose an uniform one that is unworkable. Doing so also demonstrates control, competence, and subject-matter expertise regarding the situation, which can work wonders to restore trust and credibility.

Second, cleaning up and fixing up a mess often involves getting one’s hands dirty. Specifically, there may be “guilt by association.”[47] That is, the person or persons charged with remediation may become errantly typecast in the public eye—somewhere between ultimately responsible for the mess in the first place, or

associated with hard feelings surrounding the project itself (or both). Often, when Human Research Subjects Protections non-compliance is revealed—and especially where there was a substantial, longstanding pattern of behavior—the culprits responsible may attempt to run away, hide, and feign ignorance. Specifically, they turn tail and run knowing the true extent of the mess they created when faced with the unappealing and laborious prospect of cleaning-and-fixing-up a big mess with repercussions that may taint their reputations and careers. Moreover, anyone tasked with a remediation project should be cognizant that those involved in the non-compliance may use the self-serving and treacherous yet clever ruse of implying those involved in the remediation effort must have caused the non-compliance in the first place—or else they would not be involved in the remediation. This is not to mention that those privy to what resulted in the misconduct probably will be unavailable to those cleaning-up the resulting mess, so the Remediation Team will not have the benefit of their insight and knowledge to inform reclamation efforts.

Again, these situations have the potential to become rife with finger-pointing and blame-laying, especially at the innocent feet of the remediation workers. A viable recommended strategy for the remediation crew to counter the implications of “guilt by association” is to emphatically and publicly insist they were not the parties causing the original non-compliance with Human Research Subjects Protections; they are charged with helping to formulate and implement a viable solution. Vigorous support from research institutions’ regulators and administrators of these public relations efforts should be obtained in advance of a remediation assignment.

Third, given the seriousness of allegations by the IRB or regulatory agencies, it is always a good idea to conduct a parallel internal investigation of the breadth and depth of external probes and findings (i.e., a needs assessment).[22] In other words, auditor / regulator reports should not be relied on exclusively. Typically, they

only represent a sampling of detectable, significant Human Research Subjects Protections non-compliance, which might merely scratch the surface and fail to delve extensively into the problems.[22,32,37,38,43] Naturally, once detected in substantial and patterned amounts, formulations of systematic remediation plans should be predicated on a comprehensive needs assessment survey.[22] This survey should be conducted to visually depict any patterns and connections and to keep all parties focused and honest. This survey should be reported to the IRB.[22] This will facilitate a more hands-on, practical apprehension of what happened, how it happened, and how it can be fixed and improved or prevented going forward.[39,46,48] Also, it will help prevent the remediation team from cutting corners in the interest of expediency.

Most likely, one reason significant problems occurred in the first place was that no routine internal audit mechanism was established—or, if there was one, it was not comprehensive or involved enough. An internal needs assessment is the opportunity to establish a routine audit mechanism. A comprehensive survey entails a replete inventory and description of particular types and amounts of non-compliance. These are the “what happened” factors related to the unmet Human Research Subjects Protections regulatory standards; these types of problems can be ranked in terms of amounts and severity and the aggravating circumstances of whether they were unintentional or willful.[22] Addressing each issue then can become a collaboration between the IRB, regulatory agencies and study investigators. Doing so comprehensively and systematically can be a great confidence restorer by showing that the remediation workers are ethically “true to their word.”

Fourth, remediation workers should be keenly aware that they are involved in the airing and cleaning of dirty laundry. In an industry that emphasizes image and professional reputation and prides itself on adherence and compliance with best-practices standards, there may

be fears that the workers might talk.[7,40] Remediation projects necessarily have deadlines for completion imposed by IRBs. When the work is over, there is an intrinsic risk—rather than gratitude for the Herculean tasks and egregious conditions under which they were accomplished—that the remediation workers may be disposed of over contrived reasons, much like sweeping yesterday's dirt under the rug with prejudice.[49] Any protests they register will be met with counter-protests of “sour grapes.”[49] Likewise, public awards and tokens of appreciation for their hard work and a job well done will probably not be forthcoming, because this would be a formal acknowledgement that something sordid and scandalous occurred, which would rather be buried and forgotten.[49] Also, study administrators and investigators may want to be rid of constant haunting reminders of past transgressions. The remediation work may just be over with anyway.[49] One way to allay these fears would be for remediation workers to sign self-imposed non-disclosure agreements to secure their employment and ensure their discretion.

In sum, the interest of furthering the discourse on scientific integrity, this article attempted to provide some practical cautionary considerations and recommendations regarding involvement in Human Research Subjects Protections Violation remediation and reclamation projects for those “in the trenches.” In terms of the consequences of considerations and aspects of Human Research Subjects Protections Violation remediation, this article proposes a practical, gritty real-world in-the-trenches depiction of scientific research ethics that can be synthesized and summarized as the following: “In the end, doing the right thing because it is the right thing to do will probably hurt,” or, “No good deed has ever gone unpunished.” But one still does the right thing anyway so as to look oneself in the mirror in the morning.

Rather than just a guidebook for side-stepping potential landmines, this article also tacitly highlighted that the pristine, ideal environment in which Human Subjects Protections are expected to be kept, the substantial efforts, personnel and resources expended to

do so, and the absolutist sanctions for failing to do so, have seemingly established a Zero-Defect culture around an enterprise in which human error is the norm rather than the exception.[26,50] A Zero-Defect culture[51] dictates that such standards are so sacrosanct and inviolable that the research intensive institution and its personnel could not possibly engage in their violation or even deviation—whether this is actually true or not. A Zero-Defect culture, which is commonly considered ineffective, exists where the administration is intolerant of any errors, deviations or violations; it may choose to ignore evidence of any kind. As such, workers are not held accountable or empowered by failures and become complacent and unmotivated.[51] As such, in this culture workers who identify and report and fix mistakes (i.e., “stop-the-line”) tend to be held in contempt and public opprobrium, even if they were not the source of the mistakes.[49]

This can be synergistically compounded by a scientific research culture of Paternalism.[50,51,61-71] Specifically, this is where renowned and funded medical researchers maintain a notion that they hold high authority due to their subject matter expertise in a particularly complicated and technical discipline; this tempts them to involuntarily or volitionally conduct research for their own interests and/or the greater good of science rather than in their patients' interests—because their patients “could never understand.” The two cultures together and unchecked can synergistically result in a perfect storm that spawns substantial hidden Human Research Subject non-compliance, until some unexpected event causes them to surface.[49, 26]

This destructive pattern can be countered by a commitment to a: (1) Participatory Study approach to engaging patients where they are treated less as research subjects and more as participants in a collaborative effort [52-55, 26]; and (2) a Culture of Safety that acknowledges, though mistakes and errors should be avoided, that mistakes and errors do happen as we are all human.[56-58] Both (1) and (2) together mean that (1) actively engaged Study Participants have much to teach

researchers and (2) admission and study of ethical mistakes can be learning experiences from which to enhance adherence to policy and procedures and foster innovation from lessons learned. This combined approach has the additional benefit of workers and administrators taking responsibility and accountability for their actions, thus anyone can “stop-the-line,” if they realize things have gone awry.

Conclusion

At heart this article is a stark admission that there is an unavoidable professional commitment to ensure that scientific research is conducted both ethically and competently; but failing that, remediation cannot entirely fix and make it like new again. Remediation can resurrect studies but cannot turn back the clock as if any wrongdoing or errors never happened. Nevertheless, remediation may be the one saving grace to reclaim valuable and important research despite Human Research Subjects Protections non-compliance. To fill a gap in the scientific integrity and ethics literature regarding information about the personal risks and hazards of those in the “remediation trenches,” this article provided pointers with practical implications along with recommendations of best practices.

At minimum, this article acknowledges a known problem that has been kept in the shadows due to its sensitive, controversial, and taboo nature. At best, this article serves as the impetus for more definitive and perhaps empirical works and discourses on the subject matter. Then the hushed whispers and disquietude surrounding a heretofore forbidden and censured subject will be brought to light and transformed into acceptable and credible peer-reviewed scientific articles. After all, prevention is far less costly than cure, and the focus should be on preventing scientific misconduct and ethical breaches, especially Human Subjects Protections non-compliance, rather than fixing and cleaning up the damage afterward. Yet, without a common body of knowledge about Human Subjects Protection Violations / Deviations and their corrective remediation, this less

costly prevention is improbable.

Declarations

Ethical Approval and Consent to Participate

Non-applicable, this was a commentary supported by a review of supporting open-source documents and analyses of anonymous publically available data.

Consent for Publication

Yes.

Availability of Data and Materials

Yes, publications and sources are available on-line or provided by author upon request.

Competing Interests

None declared.

Funding

This project was supported by in-kind support from the University of Texas MD Anderson Cancer Center, Dept. of Myeloma-Lymphoma, which the author gratefully acknowledges.

Authors' Contribution

Non-applicable, there is one sole Author.

Acknowledgements

The Author wishes to gratefully acknowledge in-kind support of the Department of Lymphoma and Myeloma, UT-MD Anderson Cancer Center, Houston, TX. in the preparation of this manuscript. Also, the author thanks Mr. Jasper Olsem for his encouragement in pursuing the subject matter. The author also expresses appreciation for Michael P. Ramos for proof of concept, and Ms. Aileen “Acec” Cho freelance-copy editor for proofing and copyediting drafts. The opinions expressed are solely those of the Author. Reprints and correspondence should be addressed to the author at ralph.johnson@txsg.state.tx.us, rjohnson@mdanderson.org, or jayjohnson131313@gmail.com UT-MDACC, Dept. of Lymphoma-Myeloma, Unit 429, 1515 Holcombe, Houston, Texas, 77030-400, U.S.A.. (832-750-1446; 832-372-3511)

References

1. Weisberg DF. (2014) Science in the Service of Patients: Lessons from the Past in the Moral Battle for the Future of Medical Education. *Yale J Biol Med.* Mar; 87 (1): 79–89. PMID: 24600339. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941462/pdf/yjbm_87_1_79.pdf
2. Staman J, Dijkstra H and Smits M. (2008) Afterword in *Reshaping the Human Condition: Exploring Human Enhancement* (eds.) Leo Zonneveld, Huub Dijkstra & Danielle Ringoir Rathenau Institute, The Hague 2008: 149 – 160. <https://www.parliament.uk/globalassets/documents/post/poste15.pdf>
3. Koepsell D. (2015) *Scientific Integrity and Research Ethics: An Approach from the Ethos of Science*. Springer Briefs in Ethics. Springer Nature: International, Cham, Switzerland: 1-50. <https://link.springer.com/book/10.1007/978-3-319-51277-8>
4. Institute of Medicine, National Academy of Sciences, and National Academy of Engineering. (1995) *On Being a Scientist: Responsible Conduct in Research, Second Edition*. Washington, DC: The National Academies Press. <https://doi.org/10.17226/4917>: 15-16.
5. GUIDELINES FOR RESEARCH ETHICS IN THE SOCIAL SCIENCES, LAW AND THE HUMANITIES. <https://graduateschool.nd.edu/assets/21765/guidelinesresearchethicsinthesocialscienceslawhumanities.pdf>
6. Honig B, Lampel J, Baum JA, Glynn MA, et al. Reflections on Scientific Misconduct in Management: unfortunate incidents or a normative crisis? *Academy of Management Perspectives* 32,(4). <https://doi.org/10.5465/amp.2015.0167>
7. Veldkamp CLS, Hartgerink CHJ, van Assen MALM, Wicherts JM. (2017). Who believes in the Storybook image of the scientist? *Account Res*: 24(3):127-151. doi: 10.1080/08989621.2016.1268922. Epub 2016 Dec 21. PMID: 28001440 PMID: PMC5359741 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359741/pdf/gacr-24-127.pdf>
8. National Academies of Sciences, Engineering, and Medicine; Policy and Global Affairs; Committee on Science, Engineering, Medicine, and Public Policy; Committee on Responsible Science. (2017) *Foundations of integrity in research: Core values and guiding norms in Fostering Integrity in Research*. Washington (DC): National Academies Press (US); 2017 Apr 11. https://www.ncbi.nlm.nih.gov/books/NBK475953/pdf/Bookshelf_NBK475953.pdf
9. THE WHITE HOUSE (2021) Memorandum on Restoring Trust in Government Through Scientific Integrity and Evidence-Based Policymaking. *Executive Order*: Jan 27; Washington, D.C. <https://www.whitehouse.gov/briefing-room/presidential-actions/2021/01/27/memorandum-on-restoring-trust-in-government-through-scientific-integrity-and-evidence-based-policymaking/>
10. Members of the Bipartisan Policy Center’s Science for Policy Project. (2009). *Improving the Use of Science in Regulatory Policy: Final Report. Science for Policy Project*: Aug 5: 41-45 and 49 – 51. <https://bipartisanpolicy.org/download/?file=/wp-content/uploads/2019/03/BPC-Science-Report-fnl.pdf>
11. Funk C. (2020). *Key findings about Americans’ confidence in science and their views on scientists’ role in society*. Pew Research Center: Feb 12: Washington, D.C. <https://www.pewresearch.org/fact-tank/2020/02/12/key-findings-about-americans-confidence-in-science-and-their-views-on-scientists-role-in-society/>
12. Anderson J and Rainie L. (2017) *The Future of Truth and Misinformation Online*. . Pew Research Center: Oct 19: Washington, D.C.. https://www.elon.edu/u/imagining/wp-content/uploads/sites/964/2019/07/Future_of_Info_Environment_Elon_University_Pew_10-18-17.pdf
13. National Research Council (US) and Institute of

- Medicine (US) Committee on Assessing Integrity in Research Environments. (2002) **Integrity in Research** in Integrity in Scientific Research: Creating an Environment That Promotes Responsible Conduct. Washington (DC): National Academies Press (US). https://www.ncbi.nlm.nih.gov/books/NBK208712/pdf/Bookshelf_NBK208712.pdf
14. Lenzer J, Hoffman JR, Furberg CD, Ioannidis JP; Guideline Panel Review Working Group. (2013) Ensuring the integrity of clinical practice guidelines: a tool for protecting patients. **BMJ**: Sep 17;347:f5535. doi: 10.1136/bmj.f5535. <https://www.bmj.com/content/347/bmj.f5535.long>
 15. Antes AL and Maggi Jr LB. (2021) How to conduct responsible research: A guide for graduate students. **Curr Protoc**: Mar;1(3):e87. doi: 10.1002/cpz1.87. PMID: 33740292 PMCID: PMC8277481 <https://currentprotocols.onlinelibrary.wiley.com/doi/10.1002/cpz1.87>
 16. Angelos P, Murphy TF, Sampson H, Hollings DD, et al.. (2006) Informed consent, capitation, and conflicts of interest in clinical trials: views from the field. **Surgery**: Nov; 140(5):740-8. doi: 10.1016/j.surg.2006.06.027. Epub 2006 Sep 27. PMID: 17084716 [https://linkinghub.elsevier.com/retrieve/pii/S0039-6060\(06\)00473-9](https://linkinghub.elsevier.com/retrieve/pii/S0039-6060(06)00473-9)
 17. Koepsell D. (2015) Scientific Integrity and Research Ethics: 73-83.
 18. DuBois JM, Anderson EE, Chibnall JT, Diakov L, et al. (2018). Preventing Egregious Ethical Violations in Medical Practice: Evidence-Informed Recommendations from a Multidisciplinary Working Group. **J Med Regul**: Dec; 104(4): 23–31. doi: 10.30770/2572-1852-104.4.23 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461379/pdf/nihms-1014666.pdf>
 19. DuBois JM, Anderson Emily E, Chibnall JT, Mozersky J, et al. Serious Ethical Violations in Medicine: A Statistical and Ethical Analysis of 280 Cases in the United States from 2008-2016. **Am J Bioeth**. 2019 Jan; 19(1): 16–34. doi: 10.1080/15265161.2018.1544305 PMCID: PMC6460481 NIHMSID: NIHMS1520250 PMID: 30676904 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460481/pdf/nihms-1520250.pdf>
 20. Moreno BAC and Arteaga GMII G. (2012) Violation of ethical principles in clinical research. Influences and possible solutions for Latin America. **BMC Med Ethics**. 2012; 13: 35. Published online 2012 Dec 16. doi: 10.1186/1472-6939-13-35 PMCID: PMC3543192 PMID: 23241478 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543192/pdf/1472-6939-13-35.pdf>
 21. WhiteMG. (2020) Why Human Subjects Research Protection Is Important. **Ochsner J**: Spring; 20(1): 16–33. Published online Spring 2020. doi: 10.31486/toj.20.5012 PMCID: PMC7122250 PMID: 32284679 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122250/pdf/TOJ-20-5012_16White.pdf
 22. Johnson RJ. (2015) Remediation for Human Research Subjects Protections Non-Compliance: Concepts and Approaches. **Clinical Research & Bioethics.J Clin Res Bioeth**: 6:3: 1-10. <http://dx.doi.org/4172/2155-9627.1000220>
 23. Chubin, DE. (1985) Research malpractice. **BioScience**, v35 n2 p80-89 Feb: 80-89. <https://www.jstor.org/stable/1309844>
 24. Dingell JD. (1993) Shattuck Lecture--misconduct in medical research. **N Engl J Med**: Jun 3;328(22): 1610-5. doi: 10.1056/NEJM199306033282207. <https://www.nejm.org/doi/full/10.1056/NEJM195706272562612>
 25. Burke DL. (1995) Research misconduct: deviance, due process, and the disestablishment of science. **GM Ind L Rev**. 3, 305-315. https://www.researchgate.net/profile/Dan-Burk-2/publication/281907045_Research_Misconduct_Deviance_Due_Process_and_the_Disestablishment_of_Science/links/55fdf2d308aeafc8ac6e4303/Research-Misconduct-Deviance-Due-Process-and-the-

- Disestablishment-of-Science.pdf
26. Dubois JM, Carroll K, Gibb T, Kraus E, et al. (2012) Environmental Factors Contributing to Wrongdoing in Medicine: A Criterion-Based Review of Studies and Cases. **Ethics Behav**: May 9;22(3):163-188. doi: 10.1080/10508422.2011.641832. Epub 2011 Nov 29. PMID: 23226933 PMID: PMC3515073 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3515073/>
 27. Marshall E. (2000) Scientific misconduct. How prevalent is fraud? That's a million-dollar question. **Science**: Dec 1;290(5497):1662-3. doi: 10.1126/science.290.5497.1662. PMID: 11186377 https://www.science.org/doi/10.1126/science.290.5497.1662?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed
 28. Fanelli D. (2009) How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data. **PLoS One**: May 29;4(5):e5738. doi: 10.1371/journal.pone.0005738. <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0005738>
 29. Grant D and Alfred KC. (2007) Sanctions and recidivism: an evaluation of physician discipline by state medical boards. **J Health Polit Policy Law**. Oct;32(5):867-85. doi: 10.1215/03616878-2007-033. PMID: 17855720 <https://read.dukeupress.edu/jhpl/article-abstract/32/5/867/65671/Sanctions-and-Recidivism-An-Evaluation-of?redirectedFrom=fulltext>
 30. Bankert EA. And Amdur RJ. (2010) Institutional Review Board: Management and Function: Management and Function 2nd Edition: Jones and Bartlett Publishers; Sudsbury, MA: 85. ISBN-13: 978-0763730499 ISBN-10: 0763730491 <https://www.amazon.com/Institutional-Review-Board-Management-Function/dp/0763730491>
 31. University of California. (2009) Ethics and compliance plan. Report to the Compliance and Audit Committee of the Board of Regents. July 14. <http://www.yale.edu/hrpp/>
 32. Bhatt A. (2012) Protocol deviation and violation. **Perspect Clin Res.**: Jul-Sep; 3(3): 117. doi: 10.4103/2229-3485.100663 PMID: PMC3487227 PMID: 23125964 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487227/pdf/PCR-3-117.pdf>
 33. CDC. (2010) Human Subjects Research Protection. Policy Science Administration, CDC-SA. <https://www.cdc.gov/os/integrity/docs/cdc-policy-human-research-protections.pdf>.
 34. Borysov VI, Antoniuk OI, Pashchenko OO. (2020) Peculiarities of legal responsibility for offenses in the field of clinical trials of medicines. **Wiad Lek**: 73(12 cz 2):2833-2839. PMID: 33611290 <https://pubmed.ncbi.nlm.nih.gov/33611290/>
 35. Antkowiak TM, Colum. J., and Transnat'l L. (2007) Remedial approaches to human rights violations: The Inter-American Court of human rights and beyond. **J Transnat'l L**. 351 (2007-2008). <https://heinonline.org/HOL/LandingPage?handle=hein.journals/cjtl46&div=15&id=&page=>
 36. Cohen G, and Adashi EY. (2012) In the Wake of Guatemala: The Case for Voluntary Compensation and Remediation. **AJPH**: 102, e4_e6. <https://doi.org/10.2105/AJPH.2011.300543>. <https://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2011.300543>
 37. Pereira P. Quality in clinical research activities: Role of institution/clinical trial site. **J NABoard Hospitals & Healthcare Providers**(2, 1). January-June. <https://go.gale.com/ps/i.do?id=GALE%7CA421728012&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=23191880&p=AONE&sw=w&userGroupName=anon%7Ed005b78f>
 38. Bramstedt KA. (2004) A study of warning letters issued to clinical investigators by the United States Food and Drug Administration. **Clin Invest Med**: 27(3):129-34. https://epe.lac-bac.gc.ca/100/202/300/clinical_and_investigative-ef/2004/cim_27-3/pdf/

- pg129.pdf
39. Mehra M, Kurpanek K, Petrizzo M, Brenner S, et al. (2014) The life cycle and management of protocol deviations. **Ther Inn Reg Sci**, 48, 762–77730 December 20. <https://link.springer.com/article/10.1177/2168479014530119>
 40. Benoit WL. (1997) Image repair discourse and crisis communication. **Public Relations Review** Volume 23, Issue 2, Summer 1997, Pages 177-186. [https://doi.org/10.1016/S0363-8111\(97\)90023-0](https://doi.org/10.1016/S0363-8111(97)90023-0) <https://www.sciencedirect.com/science/article/abs/pii/S0363811197900230>
 41. Robitaille DE. (2011) **The Corrective Action Handbook**, (2nd Ed.). Paton Professional Press; Chico, CA. ISBN 978-1-932828-40-5. <https://books.google.com/books?hl=en&lr=&id=PYYeAAAAQBAJ&oi=fnd&pg=PT5&dq=how+many+Corrective+Action+Plans&ots=DFIXzcJPP7&sig=LFIxrGo-YtBomJYSpZMT9EK5zGM#v=onepage&q=how%20many%20Corrective%20Action%20Plans&f=false>
 42. Massett HA, Mishkin G, Rubinstein L, and Ivy SP, et al. (2016) **Challenges facing Early Phase Trials sponsored by the National Cancer Institute: An analysis of Corrective Action Plans to improve accrual**. July 11, 22, 22, 5408 – 5416. DOI: 10.1158/1078-0432.CCR-16-0338 <https://clincancerres.aacrjournals.org/content/22/22/5408.full-text.pdf>
 43. Manuele FA. (2014) Incident investigation: Our methods are flawed. **Prof. Safety J**: October 1, 59 (10): 34–43. Paper Number: ASSE-14-10-34 <https://onepetro.org/PS/article-abstract/59/10/34/33242/Incident-Investigation-Our-Methods-are-Flawed>
 44. He Y, Yuan C, Chen L, Liu Y, et al. While it is not deliberate, much of today's biomedical research contains logical and technical flaws, showing a need for corrective action. **Int J Med Sci**. 2018; 15(4): 309–322. Published online 2018 Jan 19. doi: 10.7150/ijms.23215 PMID: PMC5835702 PMID: 29511367 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835702/pdf/ijmsv15p0309.pdf>
 45. Rettig RA. (2000) The industrialization of clinical research. **HEALTH AFFAIRS**: March/April, 19, 2. <https://doi.org/10.1377/hlthaff.19.2.129> https://www.healthaffairs.org/doi/full/10.1377/hlthaff.19.2.129?casa_token=81fc8cFB0ZcAAAAA%3Ak52r4igdSSTrwy8y3JX-JBVhf8E0GpFIUXjPLwNdTy1qlc5pEkJrxPx7hEkg2h-40GlnXyU
 46. Raddi D, Deveriniti RS, and Ganachari GS. (2020) A retrospective study: root cause analysis of reported serious adverse event and development of corrective action and preventive action for deviated serious adverse event reports at a clinical trial site management office. **Int J Clin Trials**: Aug; 7(3): 194-199. DOI: <http://dx.doi.org/10.18203/2349-3259.ijct20203106> http://klepharm.edu/media/uploads/publications/D_Article...._1.pdf
 47. Hussingerab K and Pellens M. (2019) Guilt by association: How scientific misconduct harms prior collaborators. **Research Policy**: 48, 2, Mar, 516-530. <https://doi.org/10.1016/j.respol.2018.01.012> https://www.sciencedirect.com/science/article/pii/S004873331830012X?casa_token=2YxyDOrwvFMAAAAA:ODukpr0VNNPd_KpcjfWyVjzvnA2MPByfXNnawvjr0hJy87HZbL9ONZai9cupzR4A4Dy_hA
 48. Roach JD. (2016) Quality Oversight in nursing research (Ch 6) in **Building and Sustaining a Hospital-Based Nursing Research Program** (ed. N Albert): Springer Publishing; NY, NY. 123-150. ISBN-978-0-8261-2814-7. https://books.google.com/books?hl=en&lr=&id=EJXiCgAAQBAJ&oi=fnd&pg=PA123&dq=human+subjects+deviation+CAPA+prevention&ots=6ctD1SYvB6&sig=L1NqLyUSSq8dGQ1XLB6G0YS6_gc#v=onepage&q=human%20subjects%20deviation%20CAPA%20prevention&f=false

49. Miethe TD. (1999) Individual and organizational consequences of whistleblowing in ***Whistleblowing at Work: Tough Choices in Exposing Fraud, Waste, and Abuse on the Job***, Ch. 5. (1st ed.): 17 Dec, Routledge: NY, NY. 53-75. eBook ISBN 9780429267512 <https://doi.org/10.4324/9780429267512>
50. Steele JP (2011) Antecedents and Consequences of Toxic Leadership in the U. S. Army: A Two Year Review and Recommended Solutions. Technical rept. Nov -Jun 2011. ADA545383 <https://apps.dtic.mil/sti/citations/ADA545383>
51. Deming WE (1985) Transformation of Western Style of Management. *INFORMS Journal on Applied Analytics*: May-June, 15, 3,1-146. <https://doi.org/10.1287/inte.15.3.6>. <https://pubsonline.informs.org/doi/abs/10.1287/inte.15.3.6?journalCode=inte>
52. Koepsell D. (2015) Scientific Integrity and Research Ethics: 61-71. Miller FG and Wertheimer A. (2007) Facing up to paternalism in research ethics. ***The Hastings Center Report***: 37, 3, May-June: 24-34. <https://doi.org/10.1353/hcr.2007.0044> https://onlinelibrary.wiley.com/doi/abs/10.1353/hcr.2007.0044?casa_token=hBFkefqxnbsAAAAA:Gg07TOeWLmaSmNLnksz1F0nwo6hMXdg4NEOfpwsVvjGLhaCXwQjmPplSRaF-gEfmSpMZ2J3PLbQ
53. Reilly, RC. (2010) Participatory case study. In: Mills, Albert J. and Durepos, Gabrielle and Wiebe, Elden, (eds.) ***Encyclopedia of case study research***. Sage, Thousand Oaks, CA, pp. 658-660. ISBN 9781412956703
54. Hudon C, Chouinard M-C, Bisson M, Danish A, Marlène Karam ,et al. (2021) Case study with a participatory approach: Rethinking pragmatics of stakeholder engagement for implementation research. ***Ann Fam Med***: Nov-Dec ;19(6):540-546. doi: 10.1370/afm.2717. PMID: 34750129 PMCID: PMC8575520 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575520/pdf/annalsfm_19_6_010.pdf
55. Wright MT. Participatory health research: origins and current trends. ***BGG***: Feb;64(2):140-145. doi: 10.1007/s00103-020-03264-y. Epub 2020 Dec 17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843534/pdf/103_2020_Article_3264.pdf
56. Baram M. (2021) Making clinical trials safer for human subjects. *Am Journal Law & Med*, 27 , 2-3: Perspectives on Medical Error: Reactions to the IOM Report, 2001, 253 - 282. DOI: <https://doi.org/10.1017/S0098858800011503> <https://www.cambridge.org/core/journals/american-journal-of-law-and-medicine/article/abs/making-clinical-trials-safer-for-human-subjects/F81F4E93E408732662498AB1D34F9460>
57. Pisani AR, Wyman PA, Mohr DC, and Perrino T. (2016) Human subjects protection and technology in prevention science: selected opportunities and challenges. ***Prevention Science***: 17, 765-778. DOI 10.1007/s11121-016-0664-1. <https://link.springer.com/content/pdf/10.1007/s11121-016-0664-1.pdf>
58. Weaver SJ, Lubomksi LH, Wilson RF, Pfoh ER, et al. (2013) Promoting a culture of safety as a patient safety strategy: a systematic review. *Ann Intern Med*: Mar 5;158(5 Pt 2):369-74. doi: 10.7326/0003-4819-158-5-201303051-00002 PMID: 23460092 PMCID: PMC4710092 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710092/>